344
Medical CareDay Hospital
7
22
A phase II study of metronomic oral chemotherapy with cyclophosphamide Esposito plus capecitabine and vinorelbine in metastatic breast cancer patients.
Medical CareDay Hospital
5
5
Breast Cancer prevention with fenretinide in young women at genetic and Bonanni familial risk. A phase III randomized trial
Cancer Prevention and Genetics
9
20
Breast ductal lavage in subjects with microcalcifications or at risk for breast Bonanni cancer: identification of atypical cells and assessment of proliferation
Cancer Prevention and Genetics
0
483
Randomized trial of diet, physical activity and breast cancer recurrences Bonanni DIANA 5 study
Cancer Prevention and Genetics
87
265
Efficacy of intraoperative radiotherapy compared to conventional external Veronesi Orecchia radiotherapy to prevent local relapse of breast carcinoma after breast conserving surgery.
Senology Radiotherapy
0
1306
GIM8 (OVER): A randomized trial with factorial design comparing Nolè Fulvestrant ± Lapatinib ± Aromatase inhibitors in metastatic breast cancer progressing after aromatase inhibitor therapy
Medical CareDay Hospital
4
15
Medicine
20
333
Role of HLA-G in the resistance mechanisms to trastuzumab in advanced Goldhirsch breast cancer patients with HER-2 amplified and /0r over expressed
Medicine
6
29
Adjuvant therapy for patients with breast cancer whose tumors are Goldhirsch judged to require cytotoxic therapy (ER-negative and PgR-negative). Low-dose cytotoxics as “anti-angiogenesis treatment” following induction chemotherapy.
0
9
Senology Medicine
584
Research in medical senology
A randomized trial of axillary dissection versus no axillary dissection for Veronesi Goldhirsch patients with clinically node negative breast cancer and micrometastases in the sentinel node.
0
GHEA study - Adjuvant Herceptin group
Randomized placebo controlled phase III trial with low dose tamoxifen in Bonanni women with intraepithelial breast neoplasm. TAM-01
Cancer Prevention and Genetics
27
Respiratory tract & sarcomas
0
15
Phase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) Colleoni followed by weekly paclitaxel plus metronomic cyclophosphamide ± trastuzumab as preoperative treatment of locally advanced ER e PgR negative breast cancer.
Research medical senology
11
39
A phase I/II study to assess the safety and immunogenicity of recMAGE- De Pas A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant chemo(-radio) therapy, to patients with MAGE-A3positive Non Small Cell Lung cancer (stage IB, II or III). Prot. 107240 (MAGE3-AS15-NSC-001)
90
90
Respiratory tract & sarcomas
45
Psycho-oncology
A double blind, randomized placebo controlled phase III study to assess the De Pas efficacy of recMAGE-A3 + AS15 antigen specific cancer immunotherapeutic ad adjuvant therapy in patients with resectable MAGE-A3 positive non small cell lung cancer. MAGRIT109493
14
Efficacy of telephone psychological support in reducing post-traumatic Lupo Arnaboldi stress syndrome symptoms in women diagnosed with breast cancer awaiting surgery: information strategies compared Blood test for breast cancer associated auto antibodies.
Laboratory Medicine
65
150
Respiratory tract - Melanoma
2
23
Phase II study of preoperative bevacizumab plus weekly paclitaxel, Dellapasqua carboplatin and metronomic cyclophosphamide + - trastuzumab and endocrine therapy for inflammatory breast cancer.
Research in medical senology
5
20
Analysis of the expression of a specific set of genes and tumor antigens De Pas Testori in patients with non-small cell lung cancer and melanoma. ONCO RD-001 Prot 109752
Respiratory tract & sarcomas
0
7
Helping ourselves, helping others: the young women's breast cancer Locatelli study.
Medical Oncology
25
49
A randomized, multicenter phase II study to explore whether biomarkers De Pas correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous, non small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin-based chemotherapy (gemcitabine or paclitaxel)
The HOT Study: Hormone replacement therapy opposed by low dose Bonanni Veronesi tamoxifen. A phase III trial of breast cancer prevention with low dose tamoxifen in HRT users.
Cancer Prevention and Genetics
0
478
Evaluation of the accuracy of a serological biomarker (proGRP) in the Sandri differential diagnosis in the monitoring of small cell lung cancer.
Laboratory Medicine
226
598
18F-Fluorothymidine (18F-FLT)-PET as an early predictor of response to De Cicco neo adjuvant therapy in patients with locally advanced breast carcinoma
Nuclear Medicine
10
10
Respiratory tract & sarcomas
8
8
Report on the dose to the fetus from intraoperative electron treatment of Orecchia breast cancer on a pregnant patient
Radiotherapy
5
5
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of De Pas PF-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced No small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus. A8081007
A Phase II study of cisplatin plus cyclophosphamide for patients with Locatelli previously treated, advanced, triple receptor negative breast cancer
Medical Oncology
1
1
Respiratory tract & sarcomas
20
20
A randomized multicenter phase III open label study of the efficacy and Curigliano safety of Trastuzumab - MCC-DM1 vs Capecitabine + Lapatinib, in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior Trastuzumab based therapy. BO21977.
Medical Oncology
4
4
Phase II open label single arm study of the efficacy and safety of PF- De Pas 02341066 in patients with advanced non small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus. A8081005 A phase III randomized study to compare Erlotinib and II line chemotherapy De Pas in patients with lung non small cell lung carcinoma stratified according to the proteomic profile
Respiratory tract & sarcomas
6
13
A randomized 3 arms multicentre phase III study to evaluate the efficacy Curigliano and safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), vs the combination of trastuzumab plus taxane as first line treatment in HER2-positive progressive or recurrent locally advanced or metastatic breast cancer. BO22589
Medical Oncology
8
NGR014: Randomized phase II study of NGR-hTNF in combination with De Pas standard chemotherapy versus standard chemotherapy alone in previously untreated patients with advanced non-small cell lung cancer
Respiratory tract & sarcomas
15
19
Respiratory tract & sarcomas
7
11
Sentinel node identification in breast cancer by fluorescence lymphography Veronesi P using indocyanine green dye (ICG):pilot study.
Senology
64
64
An open label phase I dose escalation study to assess the safety De Pas and immunogenicity of recPRAME+AS15 antigen specific cancer immunotherapeutic as adjuvant therapy in patients with resectable PRAME-positive NSCLC. 113174
16
16
Respiratory tract & sarcomas
2
Medical CareDay Hospital
Randomized double-blind placebo controlled phase III trial to assess the De Pas efficacy and safety of acetil-Lcarnitine in combination with cisplatincontaining chemotherapy as first line treatment of advanced or metastatic non small cell lung cancer.
2
Phase II study of metronomic oral Vinorelbine (Navelbine) plus Nolè Bevacizumab (Avastin) as first line treatment for metastatic breast cancer patients
IEO — Scientific Report 2011 — Ongoing research 2012
Colleoni
Sandri
Clinical Trials
Metronomic Capecitabine plus Docetaxel as first line treatment for Nolè metastatic breast cancer patients: a phase II trial
Lung 47
8
IEO — Scientific Report 2011 — Ongoing research 2012
345